Sutro Biopharma Shares Outstanding History (STRO)
Sutro Biopharma reported 8.6M shares outstanding at the end of fiscal 2025.
View full Sutro Biopharma company overviewSutro Biopharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 8.6M | 7.8M | +933.46% |
| 2024 | 2024-12-31 | 830,639.8 | 220,541.51 | +36.15% |
| 2023 | 2023-12-31 | 610,098.29 | 35,102.88 | +6.10% |
| 2022 | 2022-12-31 | 574,995.41 | 111,724.1 | +24.12% |
| 2021 | 2021-12-31 | 463,271.31 | 5,750.15 | +1.26% |
| 2020 | 2020-12-31 | 457,521.16 | 226,531.47 | +98.07% |
| 2019 | 2019-12-31 | 230,989.69 | 2,507.85 | +1.10% |
| 2018 | 2018-12-31 | 228,481.84 | 223,828.54 | +4810.10% |
| 2017 | 2017-12-31 | 4,653.3 | — | — |
Sutro Biopharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.6M | 15.7M | +1856.59% |
| Q1 2026 | 2026-03-31 | 16.6M | 15.7M | +1864.08% |
| Q4 2025 | 2025-12-31 | 8.6M | 7.8M | +940.19% |
| Q3 2025 | 2025-09-30 | 851,017.49 | 27,063.99 | +3.28% |
| Q2 2025 | 2025-06-30 | 847,200.47 | 28,584.63 | +3.49% |
| Q1 2025 | 2025-03-31 | 843,490.41 | 218,924.95 | +35.05% |
| Q4 2024 | 2024-12-31 | 825,264.3 | 215,166.01 | +35.27% |
| Q3 2024 | 2024-09-30 | 823,953.5 | 214,946.46 | +35.29% |
| Q2 2024 | 2024-06-30 | 818,615.84 | 213,905.43 | +35.37% |
| Q1 2024 | 2024-03-31 | 624,565.46 | 22,947.45 | +3.81% |
| Q4 2023 | 2023-12-31 | 610,098.29 | 35,102.88 | +6.10% |
| Q3 2023 | 2023-09-30 | 609,007.04 | 62,693.44 | +11.48% |
| Q2 2023 | 2023-06-30 | 604,710.41 | 117,968.09 | +24.24% |
| Q1 2023 | 2023-03-31 | 601,618.01 | 132,349.42 | +28.20% |
| Q4 2022 | 2022-12-31 | 574,995.41 | 111,724.1 | +24.12% |
| Q3 2022 | 2022-09-30 | 546,313.6 | 83,703 | +18.09% |
| Q2 2022 | 2022-06-30 | 486,742.32 | 25,327.78 | +5.49% |
| Q1 2022 | 2022-03-31 | 469,268.59 | 8,232.53 | +1.79% |
| Q4 2021 | 2021-12-31 | 463,271.31 | 5,750.15 | +1.26% |
| Q3 2021 | 2021-09-30 | 462,610.6 | 81,680.82 | +21.44% |
| Q2 2021 | 2021-06-30 | 461,414.54 | 102,625.26 | +28.60% |
| Q1 2021 | 2021-03-31 | 461,036.06 | 228,761.85 | +98.49% |
| Q4 2020 | 2020-12-31 | 457,521.16 | 226,531.47 | +98.07% |
| Q3 2020 | 2020-09-30 | 380,929.78 | 150,029.76 | +64.98% |
| Q2 2020 | 2020-06-30 | 358,789.28 | 129,517.25 | +56.49% |
| Q1 2020 | 2020-03-31 | 232,274.21 | 3,019.8 | +1.32% |
| Q4 2019 | 2019-12-31 | 230,989.69 | 2,507.85 | +1.10% |
| Q3 2019 | 2019-09-30 | 230,900.02 | 226,049.05 | +4659.87% |
| Q2 2019 | 2019-06-30 | 229,272.03 | 224,618.73 | +4827.08% |
| Q1 2019 | 2019-03-31 | 229,254.41 | — | — |
| Q4 2018 | 2018-12-31 | 228,481.84 | — | — |
| Q3 2018 | 2018-09-30 | 4,850.97 | — | — |
| Q4 2017 | 2017-12-31 | 4,653.3 | — | — |
Sutro Biopharma shares outstanding trends
Over the last five reported fiscal years, Sutro Biopharma's shares outstanding moved from 457,521.16 to 8.6M, a change of 8.1M. The latest reported quarter, Q2 2026, shows 16.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sutro Biopharma filings at SEC.gov ↗